HFS
PVLA icon

Hughes Financial Services’s Palvella Therapeutics PVLA Stock Holding History

Hughes Financial Services’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$458 Buy
3
+2
+200% +$243 ﹤0.01% 1125
2026
Q1 		$125 Hold
1
– – ﹤0.01% 1232
2025
Q4 		$105 Buy
+1
New +$85 ﹤0.01% 1055

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Frontier Capital Management
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Hughes Financial Services's PVLA Position: Q2 2026 in Review

Hughes Financial Services increased its Palvella Therapeutics (PVLA) stake by 200% in Q2 2026, buying an estimated $243 and bringing the position to 3 shares worth $458. The position accounts for ﹤0.01% of the portfolio, ranked #1125.

Hughes Financial Services first reported a position in PVLA in Q4 2025 and has held it in 3 quarters since. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Hughes Financial Services held 3 shares of Palvella Therapeutics worth $458 as of Q2 2026.
  • Hughes Financial Services bought 2 Palvella Therapeutics shares in Q2 2026, an estimated $243.
  • Palvella Therapeutics made up ﹤0.01% of Hughes Financial Services's portfolio in Q2 2026, its #1125 holding.
  • Hughes Financial Services first reported a position in Palvella Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Hughes Financial Services's 13F filing for Q2 2026, filed 20 Jul 2026.